Sahay J N, Chatterjee S S, Engler C
Clin Allergy. 1979 Jan;9(1):17-24. doi: 10.1111/j.1365-2222.1979.tb01518.x.
A double-blind, cross-over comparison of flunisolide nasal spray and its inactive aqueous vehicle has been carried out in fifty patients suffering from perennial allergic rhinitis. Patients were randomly allocated to two groups; the first group (group I) received flunisolide for 3 weeks and then placebo for 3 weeks while the regimes were given in the reverse order to the second group (group II). Patients used two insufflations of 0.1 ml in each nostril twice daily. As the active spray was presented as a 0.025% solution of flunisolide, the total daily dosage was 200 microgram. Patients were assessed on admission and at the end of each 3 week period. The results show flunisolide to be significantly superior to placebo in relieving sneezing, nasal obstruction and postnasal drip, as well as improving the quality of sleep and everday life. At the end of the trial the preferences for treatment recorded by both doctors and patients were significantly in favour of the flunisolide spray. Side effects were minor and occurred during both placebo and active phases of the trial. A short Synacthen test performed at each visit showed no evidence of adrenal suppression.
对50例常年性变应性鼻炎患者进行了氟尼缩松鼻喷雾剂与其无活性水性赋形剂的双盲交叉比较。患者被随机分为两组；第一组（I组）接受氟尼缩松治疗3周，然后接受安慰剂治疗3周，而治疗方案以相反顺序给予第二组（II组）。患者每天两次在每个鼻孔使用0.1 ml的两次喷入。由于活性喷雾剂为0.025%的氟尼缩松溶液，每日总剂量为200微克。在入院时和每3周疗程结束时对患者进行评估。结果显示，氟尼缩松在缓解打喷嚏、鼻塞和鼻后滴漏方面明显优于安慰剂，同时还能改善睡眠质量和日常生活。试验结束时，医生和患者记录的治疗偏好明显倾向于氟尼缩松喷雾剂。副作用较小，在试验的安慰剂和活性治疗阶段均有发生。每次就诊时进行的短程促肾上腺皮质激素试验未显示肾上腺抑制的证据。
